Kapusta D R, Jones S Y, Kopp U C, Dibona G F
Department of Internal Medicine, University of Iowa College of Medicine, Iowa City.
J Pharmacol Exp Ther. 1989 Mar;248(3):1039-47.
The present study was designed to investigate opioid peptide-mediated changes in renal function in conscious Sprague-Dawley rats after administration of the native opioid agonist methionine enkephalin (ME), its synthetic analog D-Ala2-methionine enkephalinamide (DALA) and the opioid antagonist naloxone. Intravenous infusion of DALA (25 micrograms/kg/min) and ME (75 micrograms/kg/min) produced no changes in mean arterial pressure, heart rate, glomerular filtration rate or effective renal plasma flow in rats with intact or bilaterally denervated kidneys. In contrast, i.v. infusion of these opioid agonists produced differing effects on the renal excretion of water and sodium; DALA produced an increase in urinary flow rate and sodium excretion and ME produced a decrease in these parameters. Changes in renal sympathetic nerve activity were not involved in producing these effects as supported by measurements of renal sympathetic nerve activity and the finding that prior bilateral renal denervation did not alter the renal responses to either agonist. The renal excretory responses to both DALA and ME infusion were prevented by pretreatment with the opioid receptor antagonist naloxone, thus suggesting an opioid receptor-mediated effect of both agonists. Intravenous bolus injections of naloxone alone produced a dose-dependent diuresis and natriuresis without producing changes in systemic or renal hemodynamics or renal sympathetic nerve activity. These studies, therefore, provide evidence that the administration of opioid receptor agonists and antagonists produce changes in the renal excretion of water and sodium via an action on renal tubular reabsorptive mechanisms which are independent of changes in systemic or renal hemodynamics or renal sympathetic nerve activity.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究旨在探讨在清醒的Sprague-Dawley大鼠中,给予天然阿片类激动剂甲硫氨酸脑啡肽(ME)、其合成类似物D-丙氨酸2-甲硫氨酸脑啡肽酰胺(DALA)和阿片类拮抗剂纳洛酮后,阿片肽介导的肾功能变化。静脉输注DALA(25微克/千克/分钟)和ME(75微克/千克/分钟)对肾脏完整或双侧去神经支配的大鼠的平均动脉压、心率、肾小球滤过率或有效肾血浆流量没有影响。相比之下,静脉输注这些阿片类激动剂对水和钠的肾排泄产生了不同的影响;DALA使尿流率和钠排泄增加,而ME使这些参数降低。肾交感神经活动的变化与这些影响的产生无关,肾交感神经活动的测量以及先前双侧肾去神经支配并未改变对任何一种激动剂的肾反应这一发现支持了这一点。阿片受体拮抗剂纳洛酮预处理可预防对DALA和ME输注的肾排泄反应,因此表明两种激动剂均有阿片受体介导的作用。单独静脉推注纳洛酮会产生剂量依赖性的利尿和利钠作用,而不会引起全身或肾脏血流动力学或肾交感神经活动的变化。因此,这些研究提供了证据,表明阿片受体激动剂和拮抗剂的给药通过作用于肾小管重吸收机制来改变水和钠的肾排泄,这与全身或肾脏血流动力学或肾交感神经活动的变化无关。(摘要截短至250字)